Rate Video

ASCO 2022 | Reducing oral mucositis in patients treated with CRT using avasopasem manganese

Paolo Bossi • 5 Jun 2022

Head and Neck Cancer Avasopasem manganese

Paolo Bossi, MD, University of Brescia, Brescia, Italy, discusses the results of a Phase III trial of avasopasem manganese for severe oral mucositis in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Factors predicting the outcome of immunotherapy to patients with head and neck cancer

Paolo Bossi • 20 Sep 2021

Role of geriatric assessment in treatment decisions for elderly patients with head and neck cancer

Paolo Bossi • 20 Sep 2021

I-TACKLE: IO followed by cetuximab in la/metastatic cutaneous squamous cell carcinomas

Paolo Bossi • 6 Jun 2022

Updates on the SINTART2 trial in patients with inoperable sinonasal epithelial tumors

Paolo Bossi • 20 Sep 2021

Related Videos

KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC

Barbara Burtness

Durvalumab plus danvatirsen for R/M HNSCC: exciting SCORES data

The risks of radioactive iodine treatment in thyroid cancer

Checkpoint inhibitors for head and neck cancer in the definitive setting?

Barbara Burtness